May 11, 2023

Ross Muken Chief Financial Officer SOPHiA GENETICS SA 185 Dartmouth Street Floor 5 Boston, MA 02116

> Re: SOPHiA GENETICS SA Form 20-F for the

Fiscal Year Ended December 31, 2022

Filed March 7, 2023 Form 6-K furnished

May 9, 2023

File No. 001-40627

Dear Ross Muken:

We have limited our review of your filing to the financial statements and related

with information so we may better understand your disclosure.

Please respond to the comment within ten business days by providing the requested

information or advise us as soon as possible when you will respond. If you do not believe our

comment applies to your facts and circumstances, please tell us why in your response.

 $\label{eq:After reviewing your response to the comment, we may have additional comments.} \\$

Form 6-K furnished May 9, 2023

Exhibit 99.3

Reconciliation of IFRS to Adjusted IFRS Statement of Profit and Loss, page $11\,$

1. Your non-IFRS presentation appears to represent a full consolidated statement of profit and loss. Please tell us why you believe your presentation is consistent with Question 102.10(a) through (c) of the Compliance and Disclosure Interpretations on Non-GAAP

Ross Muken
FirstName LastNameRoss
SOPHIA GENETICS SA Muken
Comapany

May NameSOPHiA GENETICS SA

11, 2023

May 11,

Page 2 2023 Page 2

FirstName LastName

In closing, we remind you that the company and its management are responsible for the $\,$

accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or

absence of action by the staff.

You may contact Mary Mast at (202) 551-3613 or Frank Wyman at (202) 551-3660 with any questions.

Sincerely,

Division of

Office of Life

Financial Measures.

Corporation Finance

Sciences